# ZeroStack Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ZeroStack Corp.). ## Overview ZeroStack Corp. is a U.S.-listed company with operations spanning pharmaceutical distribution, cannabis-related consumer products, and a treasury strategy centered on digital assets tied to AI infrastructure. Its operating businesses include the German-based Phatebo wholesale pharmaceutical distributor, the JustCBD consumer brand, cannabis accessories and technology, and other international distribution activities through subsidiaries in the United States, Germany, and Australia. ## Products & services • Wholesale pharmaceutical distribution • Medical cannabis and related products • CBD consumer packaged goods • Cannabis accessories and technology • Cannabis-infused beverages distribution • Digital asset treasury exposure to 0G Tokens - **Commercial & Wholesale Pharmaceuticals** (45%) — Distribution of pharmaceutical goods and medical products through Phatebo and related channels. - **House of Brands / CBD Consumer Products** (25%) — Branded hemp- and CBD-based consumer packaged goods sold through retail and specialty channels. - **Cannabis Accessories & Technology** (15%) — Consumer accessories and technology products sold under the Vessel brand and related offerings. - **Cannabis-Infused Beverages** (5%) — Distribution of cannabis-infused drink products through United Beverage Distribution. - **AI Treasury / Digital Assets** (10%) — Strategic ownership and treasury exposure to 0G Tokens and related AI ecosystem assets. - Wholesale pharmaceutical distribution - Medical cannabis and related products - CBD consumer packaged goods - Cannabis accessories and technology - Cannabis-infused beverages distribution - Digital asset treasury exposure to 0G Tokens ## Customers ZeroStack sells to pharmaceutical wholesalers, healthcare-related buyers, and international distribution partners through its commercial and wholesale business. Its branded consumer products are purchased by specialty retail channels such as smoke and vape shops, clinics, spas, pet stores, and other non-traditional retail outlets, while cannabis-related products also reach end consumers through retail and online channels. The pharmaceutical side serves buyers that need regulated supply, product breadth, and cross-border sourcing capabilities. - **Pharmaceutical wholesale customers** (primary) — Buy imported and exported pharmaceutical goods for regulated resale and healthcare supply. - **Specialty retail channels** (primary) — Purchase CBD and hemp-derived products for resale in smoke shops, vape shops, clinics, spas, and pet stores. - **Online consumers** (secondary) — Buy branded CBD, accessories, and related wellness products through e-commerce and direct channels. - **Cannabis and beverage distributors** (emerging) — Buy cannabis-infused drinks and related products for regional distribution and retail placement. - **AI/digital asset ecosystem participants** (emerging) — Indirect exposure through the 0G treasury strategy and related ecosystem investments. - Pharmaceutical distributors and wholesale buyers in Europe and beyond - Specialty retail channels for JustCBD products - Clinics, spas, pet stores, smoke shops, and vape shops - Online and direct-to-consumer buyers of branded cannabis products - Healthcare and medical-cannabis customers needing regulated supply ## Geography ZeroStack operates through subsidiaries in the United States, Germany, and Australia, with principal pharmaceutical operations in Germany. Management also describes pharmaceutical distribution across 28 countries globally, primarily in Europe, with additional sales into Asia, Latin America, and North America. Geography matters because the company’s operating model depends on local regulatory approvals, cross-border logistics, and differing legal treatment of cannabis and pharmaceutical products. - **Europe** (70%) — Management says pharmaceutical distribution is primarily in Europe and concentrated in Germany. - **North America** (15%) — Includes U.S.-based branded and distribution activities. - **Asia** (7%) — Management discloses sales into Asia. - **Latin America** (5%) — Management discloses sales into Latin America. - **Australia** (3%) — Includes Australian Vaporizers and related operations. - Principal pharmaceutical operations are based in Germany - Subsidiaries operate in the United States, Germany, and Australia - Pharmaceutical distribution spans 28 countries globally - Core sales are concentrated in Europe, with reach into Asia and the Americas - Regulatory differences by country shape product availability and channel access ## Strategy ZeroStack’s stated direction combines an AI-focused treasury strategy with operating businesses that generate cash flow from pharmaceutical distribution and branded consumer products. The company is also pursuing broader geographic reach, strategic partnerships, and acquisitions to expand its footprint and diversify sources of cash flow. Its operating model links regulated distribution businesses with a digital-asset allocation strategy centered on 0G Tokens. - **Develop the AI treasury platform around 0G** (short-term) — The company wants to create value through strategic ownership of AI-linked digital assets. - **Diversify cash flows through operating businesses** (short-term) — Pharmaceutical distribution and branded products provide operating revenue outside the treasury strategy. - **Expand geographic footprint** (medium-term) — Broader market access reduces dependence on any single country or regulatory regime. - **Use acquisitions and partnerships to scale** (medium-term) — The company has indicated that inorganic growth can supplement organic expansion. - Build an AI-focused treasury and asset management platform - Hold and deploy 0G Tokens as a strategic digital asset - Expand pharmaceutical distribution across additional markets - Use branded consumer products to build channels and customer loyalty - Pursue partnerships and acquisitions to broaden the operating base ## Risks ZeroStack faces a combination of digital-asset, regulatory, and operating-business risks. The 0G treasury strategy exposes results to token price volatility, custody and cybersecurity risk, while the pharmaceutical and cannabis businesses depend on licensing, cross-border compliance, and product-specific regulatory approvals. The company also carries early-stage execution risk because it operates multiple business lines across different legal regimes. - **0G token volatility** [high] — The company holds 0G as a strategic asset, so fair value changes can materially affect results. - **Custody and private-key loss** [high] — Digital assets require secure custody; loss or compromise could permanently reduce holdings. - **Cannabis regulatory change** [high] — Product legality, labeling, and distribution rules vary by jurisdiction and can restrict sales. - **Pharmaceutical compliance and licensing** [medium] — Wholesale distribution depends on permits, import/export approvals, and local compliance. - **Cybersecurity and operational integration** [medium] — Acquisitions and digital-asset operations increase attack surface and integration complexity. - 0G token price volatility can swing reported results materially - Custody and private-key loss could impair digital asset holdings - Cannabis and hemp products face changing legal and labeling rules - Cross-border pharmaceutical distribution depends on licenses and permits - Cybersecurity and integration risk rise with acquisitions and digital assets ## Accounting Revenue is recognized under a contract-based five-step model and is presented net of discounts, returns, rebates, duties, and taxes collected for third parties. Investors should watch inventory valuation, warranty accruals on accessory products, lease obligations, debt, and contingent liabilities because these areas can move reported earnings and balance-sheet values. Digital assets also introduce fair-value accounting sensitivity, since changes in 0G value flow through the financial statements. - **Revenue recognition for product sales** — Affects reported revenue timing and net sales - **Warranty accruals** — Affects cost of sales and liabilities - **Inventory valuation** — Affects gross margin and working capital - **Digital asset fair value** — Can create large non-operating gains or losses - **Lease and debt obligations** — Affects liquidity and fixed-charge burden - Revenue is net of discounts, returns, rebates, duties, and taxes - Point-in-time product sales drive recognition timing - Accessory products carry a six-month warranty accrual - Inventory valuation affects gross margin and write-down risk - 0G fair value changes affect reported earnings and assets - Lease, debt, and legal obligations affect leverage and liquidity --- *Last updated: 2026-04-29T05:11:42.049589+00:00*